Loading...
CADL logo

Candel Therapeutics, Inc.NasdaqGM:CADL Stock Report

Market Cap US$723.9m
Share Price
n/a
1Y60.8%
7D0.6%
1D0.1%
Portfolio Value
​
View

Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$723.9m

Candel Therapeutics (CADL) Stock Overview

A clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. More details

CADL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 97.3% below our estimate of its fair value

Earnings are forecast to grow 64.94% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market


CADL Community Fair Values

Create Narrative

See what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW487,274 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
487,274 investors already sharing narratives
View all narratives

Candel Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Candel Therapeutics
Historical stock prices
Current Share PriceUS$9.89
52 Week HighUS$11.36
52 Week LowUS$4.35
Beta-0.51
1 Month Change14.07%
3 Month Change104.76%
1 Year Change60.81%
3 Year Change724.17%
5 Year Changen/a
Change since IPO41.29%

Recent News & Updates

Seeking Alpha • Jul 04

Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

Summary Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets. I see near-term catalysts in the prostate BLA submission, Phase III AURORA NSCLC trial, and maturing glioma data, with execution risk now outweighing clinical risk. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jul 04

Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential

Summary Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets. I see near-term catalysts in the prostate BLA submission, Phase III AURORA NSCLC trial, and maturing glioma data, with execution risk now outweighing clinical risk. Read the full article on Seeking Alpha
Seeking Alpha • Feb 20

Candel Therapeutics: Entering Its Pivotal Year

Summary Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug could see an FDA submission mid-year. The shorts have melted away, and the ticker is seeing strong price action. Big risks remain due to its negative EPS and debt ratios, but that potential FDA approval and its varied proprietary platforms make Candel an attractive acquisition target. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Summary Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025. Viral therapies like CAN-2409 face commercialization challenges, but the strong phase 3 data justifies maintaining a "Buy" rating for CADL stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 01

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Summary Candel Therapeutics develops biological immunotherapies, combining anti-tumor and immune-stimulatory elements to target and destroy cancer cells. Its leading candidates, CAN-2409 and CAN-3110, show promising results in clinical trials for various cancers. CAN-2409 received multiple FDA designations, including Fast Track, Special Protocol Assessment, and Orphan Drug designation for pancreatic cancer. Unfortunately, CADL has significant financial questions, with a high cash burn rate and a short runway, which will necessitate additional funding soon, in my opinion. The company’s need to raise funds, likely through equity, may result in substantial stock dilution, leading to a "sell" rating despite promising IP. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Summary Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC achieved mOS of 28.8 months. Orphan Drug Designation is given by FDA for CAN-2409 for the treatment of patients with borderline respectable pancreatic ductal adenocarcinoma. Results from phase 2 study using CAN-2409 for the treatment of patients with non-small cell lung cancer, expected Q2 of 2024. Data readouts from two other studies expected in Q4 of 2024, both of which deal with the targeting of patients with localized prostate cancer using CAN-2409. Read the full article on Seeking Alpha
Seeking Alpha • Sep 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Candel Therapeutics (NASDAQ:CADL) on Thursday said a European drug regulator committee had given a positive recommendation to grant an orphan drug designation to the company's CAN-2409 therapy for the treatment of glioma, which is a type of tumor that occurs in the brain and spinal cord. The European Medicines Agency's (EMA) Committee for Orphan Medical Products issued the positive opinion, CADL said in a statement. CAN-2409 is a genetically modified adenovirus that is currently being evaluated in multiple phase 2 and 3 trials for lung, brain, pancreatic and prostate cancers, CADL said. The EMA's orphan designation is given to medicines developed for rare, life-threatening diseases. CADL said the orphan drug designation follows a U.S. FDA fast track designation granted in June last year for CAN-2409 to be used in combination with antiviral drug valacyclovir to treat newly diagnosed glioma. CADL stock +3.7% to $3.64 in early trading.
Seeking Alpha • Sep 07

Candel Therapeutics appoints CFO, chief medical officer

Biopharmaceutical company Candel Therapeutics (NASDAQ:CADL) appointed Jason Amello CFO and Garrett Nichols chief medical officer. Amello, whose appointment is effective Sep. 21, is replacing John Canepa. Canepa has decided to pursue other interests and spend more time with his family. Amello joins from the rare disease biotech company Saniona, while Nichols joins from Istari Oncology. Source: Press Release
Seeking Alpha • Oct 21

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Candel is an immunotherapy company with a lead asset, CAN-2409, in Phase 3 clinical trials for prostate cancer. CAN-2409 has a strong clinical safety data across >700 patients and the potential to become a transformative therapy in prostate cancer. With ongoing pivotal clinical trials across 2 stages of prostate cancer along with trials in glioma and NSCLC, CAN-2409 will serve as a key catalyst for Candel. Depending on the binary event of the lead clinical trial, Candel Therapeutics will be in a position to expand CAN-2409’s use for more indications, expand the platform, and engage in more partnerships.

Shareholder Returns

CADLUS BiotechsUS Market
7D0.6%3.4%-0.4%
1Y60.8%37.9%18.4%

Return vs Industry: CADL exceeded the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: CADL exceeded the US Market which returned 18.4% over the past year.

Price Volatility

Is CADL's price volatile compared to industry and market?
CADL volatility
CADL Average Weekly Movement11.8%
Biotechs Industry Average Movement10.5%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: CADL's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CADL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200355Paul-Peter Takwww.candeltx.com

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.

Candel Therapeutics, Inc. Fundamentals Summary

How do Candel Therapeutics's earnings and revenue compare to its market cap?
CADL fundamental statistics
Market capUS$723.91m
Earnings (TTM)-US$54.42m
Revenue (TTM)n/a
0.0x
P/S Ratio
-13.3x
P/E Ratio

Is CADL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CADL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$54.42m
Earnings-US$54.42m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.74
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio34.4%

How did CADL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 23:59
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Candel Therapeutics, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Alec StranahanBofA Global Research
Brian Kemp DolliverBrookline Capital Markets